No Data
No Data
Beijing Science Sun Pharmaceutical (300485.SZ): The company's main business does not currently involve the CXO field.
Saisun Pharmaceutical (300485.SZ) stated on the investor interaction platform on October 11 that the company's main business does not currently involve the CXO field.
Beijing Science Sun Pharmaceutical (300485.SZ): Junyuan Pharmaceutical's pharmaceutical production license change.
Gelonghui, September 25th | Beijing science sun pharmaceutical (300485.SZ) announced that its subsidiary, Shenyang Junyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Junyuan Pharmaceutical"), recently obtained the "Drug Production License" issued by the Liaoning Provincial Drug Administration. The matters involved in this change include: allowing the company to change the production site of the marketed drug Zifeng Tuogu Tablets (each tablet weighs 0.29g) (National Drug Approval No. Z21020728) from 103 Lane 6, Lingyun Street, Dongling District, Shenyang City to Building 9, Building 22, 603, Mainzi Tun, Hunnan District, Shenyang City, with no other changes.
Saisheng Pharmaceutical: 2024 Semi-Annual Report
Saisheng Pharmaceutical: 2024 Semi-Annual Report Summary
Beijing Science Sun Pharmaceutical (300485.SZ): The net loss in the first half of the year was 105 million yuan, turning into a loss year-on-year.
Beijing Science Sun Pharmaceutical (300485.SZ) released its semi-annual report on August 27th, with revenue of 0.215 billion yuan, a year-on-year decrease of 21.03%, net loss of 0.105 billion yuan, a year-on-year loss, non-GAAP net income of 18.088 million yuan, a year-on-year decrease of 8.11%, and basic EPS of -0.22 yuan.
Beijing Science Sun Pharmaceutical (300485.SZ): The national cancer center/ethics committee of the Beijing Union Medical College of China Medical Science Academy approved the report on the injection of humanized anti-VEGF monoclonal antibodies.
On July 22nd, Gelunhui reported that Beijing Science Sun Pharmaceutical (300485.SZ) has developed a "humanized anti-VEGF monoclonal antibody injection" which has been approved by the Ethics Committee of the National Cancer Center/Beijing Union Medical College Cancer Hospital of China Academy of Medical Sciences. This marks the confirmation of Phase III clinical trial program and the approval for substantial implementation of the trial. Bevacizumab is a humanized anti-VEGF monoclonal antibody that can be widely used as an anti-angiogenic drug for various tumors, by inhibiting the generation of new blood vessels in tumors via blocking VEGF. This can cut off the blood supply to tumor regions, inhibiting the growth and metastasis of tumors.
No Data
No Data